New hope for lung cancer that outsmarts first-line drugs
NCT ID NCT07414927
First seen Feb 18, 2026 · Last updated May 15, 2026 · Updated 13 times
Summary
This study tests a new drug, BL0020, in 48 adults whose lung cancer changed from non-small cell to small cell after initial targeted therapy. The drug aims to shrink tumors and control the disease. Participants must have this specific cancer transformation and meet other health criteria.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL CARCINOMA OF LUNG are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai Chest Hospital
Shanghai, 200030, China
Contact
Contact
Conditions
Explore the condition pages connected to this study.